Management of Refractory Nausea in Elderly Patients

First-Line Options for Breakthrough Nausea

The American College of Physicians and other guideline societies recommend adding metoclopramide 10 mg IV or prochlorperazine 5-10 mg IV as the next antiemetic agent for breakthrough nausea in elderly patients when 5-HT3 antagonists like ondansetron have failed, due to their dopaminergic antagonism 1, 2
Metoclopramide has the added benefit of prokinetic effects that may help with gastric emptying, and is recommended at a reduced dose of 5-10 mg in elderly patients due to increased sensitivity 1, 2
Prochlorperazine 5-10 mg IV is an alternative dopamine antagonist with similar efficacy, and should be used at the lower end of dosing (5 mg) in elderly patients 1, 2
Haloperidol 0.5-1 mg IV is another effective option, particularly if delirium is contributing to symptoms, and should be started at 0.5 mg in elderly patients and titrated cautiously 1, 3, 4

The National Comprehensive Cancer Network recommends adding dexamethasone 2-8 mg IV to the antiemetic regimen, as corticosteroids have been shown to enhance antiemetic efficacy when combined with other agents 1, 4, 5
The addition of dexamethasone 4 mg daily to ondansetron decreases nausea, though the effect is modest, and lower doses (2-4 mg) are appropriate for elderly patients 4, 5
Lorazepam 0.5-1 mg IV should be considered if anxiety is contributing to the nausea, with reduced doses (0.25-0.5 mg) in elderly patients and a maximum of 2 mg in 24 hours 1, 3, 4, 5

The American Geriatrics Society recommends assessing for underlying causes that may be contributing to refractory nausea, including electrolyte abnormalities, constipation, urinary retention, and gastroesophageal reflux 2, 3, 4
Checking for electrolyte abnormalities (particularly hyponatremia, hypercalcemia) and correcting them is crucial 4, 2
Evaluating for constipation or urinary retention, both common in elderly patients and easily reversible, is also important 2, 3

The American College of Clinical Pharmacology recommends starting with lower doses of all antiemetics in elderly patients due to increased sensitivity to side effects and altered pharmacokinetics 1, 4, 5
Dose reductions are particularly important for benzodiazepines and antipsychotics, with elderly patients having decreased clearance and increased bioavailability of many antiemetics 4, 5, 3

The National Comprehensive Cancer Network advises against simply repeating ondansetron if a 5-HT3 antagonist has failed, and instead recommends switching to a different mechanism of action 2, 1
Avoiding high doses in elderly patients is crucial, as the risk of adverse effects increases substantially with standard adult dosing 1, 4
The American Academy of Hospice and Palliative Medicine recommends against abruptly discontinuing benzodiazepines if used, and instead advises tapering gradually to avoid withdrawal 4, 5, 1